Table 2.

End-of-Treatment Data for Presence or Absence of Insomnia Episodes.

Measures at End-of Treatment	Occurrence of Insomnia		No Occurrence of Insomnia
	M	SD	M	SD
Sleep Diaries
TST (min)	369.18	49.98	405.51	52.69
TWT (min)	31.02	11.01	39.10	17.86
SOL (min)	12.96	5.04	16.39	10.98
WASO (min)	8.88	7.11	12.77	10.43
TWAK (min)	9.18	7.64	9.95	7.04
TIB (min)	400.20	45.76	444.61	58.74
SE (%)	92.14	3.02	91.24	3.56
NWAK	0.86	0.91	1.27	1.12
Sleep Quality	6.51	1.26	6.72	0.98
Daytime Sleepiness	4.41	2.07	3.73	2.16
Daytime Tiredness	4.61	1.85	4.02	1.85
PSAS Total*	29.14	6.62	22.64	3.91
Cognitive	18.29	6.47	12.64	2.62
Somatic	10.86	1.77	10.00	2.79
GSES*	4.86	2.41	2.18	1.40
ISI	10.14	3.48	7.45	3.24
KIMS Total	141.14	18.77	131.82	15.40
Observe	40.29	7.70	35.00	6.59
Describe	29.86	6.74	30.09	7.33
Awareness	31.43	7.76	31.82	6.01
Accept	35.14	5.93	31.00	6.51
PANAS
Positive	36.14	6.57	35.00	6.37
Negative	17.86	5.40	14.27	2.94
Total Weeks with Insomnia	30.71	11.01	1.91	2.81

Note. Analyses were conducted on selected variables of interest. Asterisk (*) indicates significant difference between groups. Sleep quality ranges from 1 (very poor) to 10 (excellent). Daytime sleepiness and tiredness are rated from 1 to 10 with higher numbers reflecting higher levels of sleepiness / tiredness respectively.